CD8A and cancer: When CD8+ and CD4+ T lymphocytes are chronically activated, such as in the context of cancer, their effector functions are progressively inhibited, particularly through the expression of immune checkpoint receptors, including PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)49.